(Q51973672)

19 April 2018

title

Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. (English)

1 reference

19 April 2018

0 references

1 reference

8

1 reference

19 April 2018

Nikolaus Kleindienst

9

object named as

Nikolaus Kleindienst

1 reference

19 April 2018

11

Hans-Jürgen Möller

1 reference

19 April 2018

1

Michael Riedel

1 reference

19 April 2018

Norbert Müller

10

object named as

Norbert Müller

1 reference

19 April 2018

author name string

Ilja Spellmann

2

1 reference

19 April 2018

Martin Strassnig

3

1 reference

19 April 2018

Anette Douhet

4

1 reference

19 April 2018

Sandra Dehning

5

1 reference

19 April 2018

Markus Opgen-Rhein

6

1 reference

19 April 2018

Rosamaria Valdevit

7

1 reference

19 April 2018

publication date

14 July 2007

1 reference

19 April 2018

European Archives of Psychiatry and Clinical Neuroscience

published in

1 reference

19 April 2018

volume

257

1 reference

19 April 2018

issue

6

1 reference

19 April 2018

page(s)

360-370

1 reference

19 April 2018

https://scigraph.springernature.com/pub.10.1007/s00406-007-0739-x

exact match

0 references

cites work

Cognitive function in schizophrenia: association with negative and positive symptoms.

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0739-X

Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0739-X

Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0739-X

Should schizophrenia be treated as a neurocognitive disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0739-X

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0739-X

Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0739-X

Cognition, negative symptoms, and diagnosis: a comparison of schizophrenic, bipolar, and control samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0739-X

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0739-X

Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0739-X

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0739-X

Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0739-X

Fortnightly review. Treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0739-X

Early treatment-induced improvement of negative symptoms predicts cognitive functioning in treatment-naive first episode schizophrenia: a 2-year followup

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0739-X

What are the functional consequences of neurocognitive deficits in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-007-0739-X

A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia.

21 January 2018

1 reference

12 December 2020

The NIMH-MATRICS consensus statement on negative symptoms

1 reference

12 December 2020

Stability and course of neuropsychological deficits in schizophrenia

1 reference

12 December 2020

Positive and negative symptoms in schizophrenia: attentional performance correlates

1 reference

12 December 2020

Should cognitive deficit be a diagnostic criterion for schizophrenia?

1 reference

12 December 2020

Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.

1 reference

12 December 2020

The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia.

1 reference

12 December 2020

Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia

1 reference

12 December 2020

Cognitive functioning in the early course of first-episode schizophrenia spectrum disorders: timing and patterns.

1 reference

12 December 2020

COMPARATIVE STUDIES OF SOME PSYCHOLOGICAL TESTS FOR CEREBRAL DAMAGE.

1 reference

12 December 2020

Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action

1 reference

12 December 2020

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

1 reference

12 December 2020

The role of negative symptoms and cognitive dysfunction in schizophrenia outcome.

1 reference

12 December 2020

Development, disease and degeneration in schizophrenia: a unitary pathophysiological model

1 reference

12 December 2020

Treatment of cognitive dysfunction in schizophrenia

1 reference

12 December 2020

Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study

1 reference

12 December 2020

Neurocognition and long-term prediction of quality of life in outpatients with severe and persistent mental illness.

1 reference

12 December 2020

A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study

1 reference

12 December 2020

Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia

1 reference

12 December 2020

Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis

1 reference

12 December 2020

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

1 reference

12 December 2020

The functional significance of symptomatology and cognitive function in schizophrenia

1 reference

12 December 2020

Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum

1 reference

12 December 2020

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol

1 reference

12 December 2020

Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia

1 reference

12 December 2020

Correlates of cognitive deficits in first episode schizophrenia

1 reference

12 December 2020

Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning.

1 reference

12 December 2020

Do specific neurocognitive deficits predict specific domains of community function in schizophrenia?

1 reference

12 December 2020

Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride

1 reference

12 December 2020

A comparison of clustering solutions for cognitive heterogeneity in schizophrenia

1 reference

12 December 2020

Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis

1 reference

12 December 2020

Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior

1 reference

12 December 2020

Social-Adaptive Functioning Evaluation (SAFE): a rating scale for geriatric psychiatric patients

1 reference

12 December 2020

Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review

1 reference

12 December 2020

Memory deficits in patients with schizophrenia: preliminary data from the Wechsler Memory Scale-Third Edition support earlier findings

1 reference

12 December 2020

Neurocognitive deficits and social functioning in outpatients with schizophrenia

1 reference

12 December 2020

Atypical antipsychotics: are some more atypical than others?

1 reference

12 December 2020

Cognitive functioning and positive and negative symptoms in schizophrenia

1 reference

12 December 2020

The negative component in schizophrenia

1 reference

12 December 2020

Coding and recall of categorized material in aphasics

1 reference

12 December 2020

Is it possible to be schizophrenic yet neuropsychologically normal?

1 reference

12 December 2020

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

12 December 2020

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

1 reference

12 December 2020

One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.

1 reference

12 December 2020

Anticholinergic effects on memory: benztropine versus amantadine.

1 reference

12 December 2020

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

12 December 2020

Cognitive factors in schizophrenia: causes, impact, and treatment.

1 reference

12 December 2020

Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms

1 reference

12 December 2020

Neurocognitive correlates of positive and negative syndromes in schizophrenia

1 reference

12 December 2020

The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone

1 reference

12 December 2020

Neurocognitive functioning in patients with first-episode schizophrenia : results of a prospective 5-year follow-up study.

1 reference

12 December 2020

The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings

1 reference

12 December 2020

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

12 December 2020

Symptom patterns and subgrouping of schizophrenic patients: significance of negative symptoms assessed on admission

1 reference

12 December 2020

10.1007/S00406-007-0739-X

Identifiers

DOI

1 reference

19 April 2018

PubMed ID

17629731

1 reference

19 April 2018